RedChip Companies
|
Weekly Newsletter
|
|
|
Sharps Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and a 10-Year Purchase Agreement for Over $400 Million from Nephron Pharmaceuticals
|
Sharps Technology (Nasdaq: STSS), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, and Nephron Pharmaceuticals (“Nephron”), a privately owned U.S. leader in contract manufacturing and 503B outsourcing, signed an Asset Purchase Agreement (APA) for Sharps to acquire Nephron’s InjectEZ specialty syringe manufacturing facility. This includes a 10-Year purchase agreement for over $400 Million from Nephron Pharmaceuticals for Sharps’ next-generation copolymer prefillable syringe systems. Product delivery is scheduled to begin in the first quarter of 2024 with revenue totaling approximately $30 Million for the first 12 months of production and subsequent revenue of over $45 Million per year beginning in 2025 and continuing through 2033.
For more information, visit www.sharpstechnology.com
|
BullFrog AI Announces Positive Data from Preclinical Study Evaluating Novel Prodrug of Mebendazole for Treatment of Glioblastoma
BullFrog AI (Nasdaq: BFRG), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced positive data in a preclinical study investigating the anti-cancer activity of a novel prodrug of mebendazole for the treatment of glioblastoma. The study assessed the relative efficacy of BF-222, a novel formulation of mebendazole that has been evaluated in clinical trials, and BF-223, a novel prodrug of mebendazole with improved solubility and bioavailability relative to BF-222, compared with placebo in mice that had been implanted with tumor cells as a model for human glioblastoma.
|
Reviva Announces Last Patient Evaluated In Pivotal Phase 3 Recover Trial For Brilaroxazine In Schizophrenia
Reviva Pharmaceuticals (Nasdaq: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that the last patient in its global pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia has now completed the study. Topline data from RECOVER are expected in October 2023. Brilaroxazine is a serotonin-dopamine stabilizer with multifaceted activity designed to improve schizophrenia symptoms and accompanying neuroinflammation.
|
|
|
Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors
Lantern Pharma (Nasdaq: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced the dosing of the first patient in the Phase 1 clinical trial evaluating Lantern’s investigational new drug LP-184 in patients with advanced solid tumors.
|
Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures
Soligenix (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today two-year stability of its thermostabilized bivalent and trivalent filovirus vaccine candidates at temperatures of 40 degrees Celsius (104 degrees Fahrenheit) when formulated in a single vial, needing reconstitution only with sterile water immediately prior to use. This follows the previous successful demonstration of 100% protection of non-human primates (NHPs) against lethal Sudan ebolavirus and Marburg marburgvirus challenge with the bivalent vaccine.
|
|
|
Small Stocks Big Money™ Podcasts
|
|
|
Upcoming Events |
|
|
|
NASDAQ: SPI - SPI Energy |
4:15pm Eastern |
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. |
|
|
|
|
NASDAQ: STSS - Sharps Technology |
4:15pm Eastern |
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. |
|
|
Archive Events |
|
|
|
NYSE AMERICAN: SBEV - Splash Beverage Group |
Meeting Duration 41 minutes |
Splash Beverage Group is constantly innovating, presenting exciting, new, natural, and healthy drinks that delight the body and inspire the mind. |
|
|
|
|
NASDAQ: RVPH - Reviva Pharmaceuticals Holdings |
Meeting Duration 46 minutes |
Reviva is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. |
|
|
Lesson of the Week
Dollar cost averaging is one way to combat the volatility in small-caps.
|
|
|
MidSouth Week in Review
For the month the S&P is down 4.1%, for a typical September return.
|
|
|
You are receiving this email because your email is subscribed to our mailing list.
Click here to update your subscription or unsubscribe your email address.
Copyright © 2023. All rights reserved.
|
© 2023 RedChip , All rights reserved
|
|
|
|
|